About: Empirical Treatment and Prevention of COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Empirical Treatment and Prevention of COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Empirical Treatment and Prevention of COVID-19
Source	Medline; PMC
abstract	The rapid spread of severe acute respiratory coronavirus syndrome 2 (SARS-CoV-2) in the population and throughout the cells within our body has been developing. Another major cycle of coronavirus disease 2019 (COVID-19), which is expected in the coming fall, could be even more severe than the current one. Therefore, effective countermeasures should be developed based on the already obtained clinical and research information about SARS-CoV-2. The aim of this review was to summarize the data on the empirical treatment of COVID-19 acquired during this SARS-CoV-2 infection cycle; this would aid the establishment of an appropriate healthcare policy to meet the challenges in the future. The infectious disease caused by SARS-CoV-2 is characterized by common cold along with hypersensitivity reaction. Thus, in addition to treating common cold, it is essential to minimize the exposure of cells to the virus and to mitigate the uncontrolled immune response. A proper combination of antiviral agents, immune modulators such as prednisolone, and anticoagulants such as heparin and anti-C5a antagonists could be employed to minimize lung damage and prevent systemic involvements. Finally, strategies to achieve population immunity against SARS-CoV-2 should be developed through understanding of the interaction between the immune system and the virus.
has issue date	2020-06-22(xsd:dateTime)
bibo:doi	10.3947/ic.2020.52.2.142
bibo:pmid	32476308
has license	cc-by-nc
sha1sum (hex)	bea48141294470f517b5cb8a435b313f429a94b5
schema:url	https://doi.org/10.3947/ic.2020.52.2.142
resource representing a document's title	Empirical Treatment and Prevention of COVID-19
has PubMed Central identifier	PMC7335654
has PubMed identifier	32476308
schema:publication	Infect Chemother
resource representing a document's body	covid:bea48141294470f517b5cb8a435b313f429a94b5#body_text
is schema:about of	named entity 'IMMUNE SYSTEM' named entity 'MITIGATE' named entity 'INVOLVEMENTS' named entity 'REVIEW' named entity 'PREDNISOLONE' named entity 'COMING' named entity 'OBTAINED' covid:arg/bea48141294470f517b5cb8a435b313f429a94b5 named entity 'SARS-CoV-2' named entity 'virus' named entity 'empirical treatment' named entity 'anticoagulants' named entity 'antiviral agents' named entity 'virus' named entity 'Theophylline' named entity 'endothelial NOS' named entity 'NSAIDs' named entity 'virus' named entity 'gut microbiome' named entity 'basic treatment' named entity 'hypersensitivity reaction' named entity 'infection' named entity 'COVID' named entity 'older age' named entity 'ssRNA' named entity 'asthma' named entity 'pathophysiological' named entity 'oral medication' named entity 'Vitamin' named entity 'extracorporeal membrane oxygenation' named entity 'non-nucleoside reverse transcriptase inhibitors' named entity 'epithelium' named entity 'oseltamivir' named entity 'immune response' named entity 'heparin' named entity 'hypersensitivity reactions' named entity 'methylprednisolone' named entity 'thrombin' named entity 'COVID-19' named entity 'upper respiratory' named entity 'coronavirus' named entity 'SARS-CoV-2' named entity 'chloroquine' named entity '2, 3' named entity 'mechanical ventilator' named entity 'postexposure prophylaxis' named entity 'inoculation' named entity 'nebulization' named entity 'immune responses' named entity 'nafamostat' named entity 'antagonist' named entity 'HIV' named entity 'T lymphocyte' named entity 'northern hemisphere' named entity 'infection' named entity 'cyclic guanosine monophosphate' named entity 'convalescent serum' named entity 'allergic symptoms' named entity 'hydroxychloroquine' named entity 'cytokine' named entity 'hypersensitivity pneumonitis' named entity 'symptom' named entity 'RNA' named entity 'agonist' named entity 'dapsone' named entity 'emtricitabine' named entity 'SARS-CoV-2' named entity 'Human immunodeficiency virus' named entity 'chest radiography' named entity 'high-risk' named entity 'Cimetidine' named entity 'PPAR-γ' named entity 'inflammatory process' named entity 'risk factors' named entity 'interleukins' named entity 'pneumonia' named entity 'line defense' named entity 'epidemic' named entity 'Lopinavir/ritonavir' named entity 'SARS-CoV-2' named entity 'nucleotide' named entity 'false negative results'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software